Completed NA INTERVENTIONAL 2-arm NCT02540486

Long Acting Insulin Glargine Titration Web Tool (LTHome) vs Enhanced Usual Therapy of Glargine Titration (INNOVATE)

A 12 Week, Parallel, Open-label, Randomized, Multi-center Study Evaluating Use, Safety and Effectiveness of a Web Based Tool vs. Enhanced Usual Therapy of Glargine Titration in T2DM Patients With a 4 Week Safety Extension

Sponsor: LMC Diabetes & Endocrinology Ltd.

Conditions Type 2 Diabetes Mellitus

Interventions Diabetes Education Long-acting insulin glargine titration web tool (LTHome)

Updated 5 times since 2017 Last updated: Sep 1, 2015 Started: Dec 31, 2013 Primary completion: Mar 31, 2015 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02540486, this NA trial focuses on Type 2 Diabetes Mellitus and remains completed. Sponsored by LMC Diabetes & Endocrinology Ltd., it has been updated 5 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

LMC Diabetes & Endocrinology Ltd.
Sanofi

Data source: LMC Diabetes & Endocrinology Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada